Phase 1/2Recruiting
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
- Sponsor
- Biolingus (Industry)
- Enrolment
- 15 planned
- Conditions
- Diabete Type 2
- Interventions
- Liraglutide; Placebo
- Ages
- adults, older adults
- Registry
- NCT05268237
Full record on ClinicalTrials.gov
From the registry
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
Primary outcomes
- Incidence, nature and severity of adverse events
History
Study completion
Primary completion
Last registry update
Started
Registered